Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
BPC-157 (BPC) is a healing peptide, at the preclinical stage in the published literature. Body Protection Compound-157, a pentadecapeptide derived from human gastric juice that has shown remarkable healing properties across multiple tissue types.
Body Protection Compound-157, a pentadecapeptide derived from human gastric juice that has shown remarkable healing properties across multiple tissue types.
| Research Status | Preclinical |
|---|---|
| Half-Life | 4-6 hours |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 250-500 mcg |
Promotes angiogenesis, protects endothelium, increases growth factor expression including VEGF and EGF. Interacts with nitric oxide and dopamine systems.
Body Protection Compound-157, a pentadecapeptide derived from human gastric juice that has shown remarkable healing properties across multiple tissue types.
Promotes angiogenesis, protects endothelium, increases growth factor expression including VEGF and EGF. Interacts with nitric oxide and dopamine systems.
BPC-157 is at the following stage in the published literature: Preclinical. All information is for research and educational purposes only.
Reported half-life: 4-6 hours.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.